Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders

抑制FABP5在癌症、牛皮癣和焦虑症中表现出活性

Results from Several Research Studies Presented at the Annual ICRS Symposium

ICRS年度研讨会上发表的多项研究结果

SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that George Warren, Ph.D., Principal Scientist at Artelo, Myles Osborn, Medicinal Chemist at Artelo, and Matthew Jones, Ph.D.

加利福尼亚州索拉纳海滩，2024年7月2日（环球通讯社）--Artelo Biosciences，Inc.（纳斯达克：ARTL），一家临床阶段制药公司，专注于调节脂质信号通路，为患有癌症、疼痛、皮肤病和神经系统疾病的人开发治疗方法，今天宣布，Artelo首席科学家乔治·沃伦博士，Artelo药物化学家迈尔斯·奥斯本博士和Matthew Jones博士。

candidate from the Laviolette laboratory at the University of Western Ontario, Canada, each presented results from research studies demonstrating the broad therapeutic potential of Fatty Acid Binding Protein 5 (FABP5) inhibition at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium.

来自加拿大西安大略大学Laviolette实验室的候选人在第34届国际大麻素研究学会（ICRS）年会上提交了研究结果，证明了脂肪酸结合蛋白5（FABP5）抑制的广泛治疗潜力。

The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain..

ICRS研讨会将于2024年6月30日至7月5日在西班牙萨拉曼卡举行。。

Targeting FABP5, a promising new approach to treat cancer, was featured in the presentation “Efficacy of ART26.12, a Novel Fatty Acid Binding Protein 5 Inhibitor, in an Orthotopic HCT-116-LUC Human Colon Cancer Model.” Myles Osborn discussed novel preclinical data showing a direct anti-tumoral effect of oral treatment with ART26.12.

靶向FABP5是一种有前途的治疗癌症的新方法，在“ART26.12（一种新型脂肪酸结合蛋白5抑制剂）在原位HCT-116-LUC人结肠癌模型中的功效”的演讲中得到了介绍。“Myles Osborn讨论了新的临床前数据，显示了ART26.12口服治疗的直接抗肿瘤作用。

These data are also supportive of Artelo’s planned development of ART26.12 in chemotherapy-induced peripheral neuropathy, where ART26.12 may be able to aid in treatment of the underlying cancer, in addition to the debilitating effects of painful neuropathies..

这些数据也支持Artelo计划在化疗引起的周围神经病中开发ART26.12，其中ART26.12除了疼痛性神经病的衰弱作用外，还可能有助于治疗潜在的癌症。。

Beyond development for pain and cancer, ART26.12 has also shown the potential for therapeutic activity in dermatologic conditions. FABP5 was first identified in psoriatic lesions and there is evidence to suggest that upregulation of FABP5 contributes to the pathology of psoriasis. Regarding the data in his presentation, “A Novel Fatty Acid-binding Protein 5 Inhibitor Shows Efficacy in Preclinical Models of Psoriasis,” George Warren, Ph.D.

除了疼痛和癌症的发展之外，ART26.12还显示出在皮肤病中具有治疗活性的潜力。FABP5首先在银屑病病变中被发现，有证据表明FABP5的上调有助于银屑病的病理学。关于他演讲中的数据，“一种新型脂肪酸结合蛋白5抑制剂在银屑病的临床前模型中显示出疗效”，乔治·沃伦博士。

commented, “We are pleased to share novel data showing that our lead FABP5 inhibitor, ART26.12, demonstrated compelling data in preclinical models of psoriasis. In this study, ART26.12 reduced the severity of histopathological markers of skin damage and reduced markers of oxidative stress, chemokines, cytokines, and keratinocyte proliferation, and increased antimicrobial peptides.

评论道：“我们很高兴分享新的数据，显示我们的主要FABP5抑制剂ART26.12在牛皮癣的临床前模型中表现出令人信服的数据。在这项研究中，ART26.12降低了皮肤损伤的组织病理学标志物的严重程度，减少了氧化应激标志物，趋化因子，细胞因子和角质形成细胞增殖，并增加了抗菌肽。

Results were obtained using a standard imiquimod mouse model, which demonstrated ART26.12 had similar levels of activity as Sotyktu (deucravacitinib), an oral tyrosine kinase 2 inhibitor approved by the U.S. Food and Drug Administration in 2022 to treat psoriasis. Sales of Sotyktu may reach $4 billion by the end of the decade, according to Bristol Myers Squibb.”.

使用标准咪喹莫特小鼠模型获得结果，该模型证明ART26.12具有与Sotyktu（deucravacitinib）相似的活性水平，Sotyktu（deucravacitinib）是美国食品和药物管理局于2022年批准用于治疗牛皮癣的口服酪氨酸激酶2抑制剂。据百时美施贵宝（Bristol-Myers Squibb）称，Sotyktu的销售额可能在本十年末达到40亿美元。”。

In addition to ART26.12, another one of Artelo’s FABP5 inhibitors was featured in a presentation entitled, “Inhibition of Fatty Acid Binding Protein 5 Prevents Stress-induced Anxiety and Depressive-Like Behavioral Symptoms and Reverses Stress-induced Inhibition of Hippocampal Neurogenesis” where Matthew Jones discussed new results from ongoing studies being conducted at the laboratory of Dr.

除了ART26.12之外，Artelo的另一种FABP5抑制剂也出现在题为“抑制脂肪酸结合蛋白5可预防压力引起的焦虑和抑郁样行为症状，并逆转压力引起的海马神经发生抑制”的演讲中，其中Matthew Jones讨论了在Dr。

Steven Laviolette. The data showed that Artelo’s FABP5 inhibitor SBFI103 improved depressive-like behaviors in rats after chronic unpredictable stress, associated with increases in markers of neurogenesis, a critical process in which newly formed neural cells are added to the existing neural network.

史蒂文·拉维奥莱特。数据显示，Artelo的FABP5抑制剂SBFI103改善了慢性不可预测压力后大鼠的抑郁样行为，这与神经发生标志物的增加有关，神经发生标志物是将新形成的神经细胞添加到现有神经网络中的关键过程。

“This new data supports our laboratory’s earlier work showing SBFI103 reduces anxiety and increased fear memory extinction. These studies implicate a role for the cannabinoid receptor 2 mediating the effects of FABP5 inhibition in the brain,” concluded Jones..

琼斯总结道：“这项新数据支持了我们实验室早期的工作，表明SBFI103可以减少焦虑，增加恐惧记忆的消退。这些研究暗示大麻素受体2在介导大脑中FABP5抑制作用中起作用。”。。

“We are pleased to share the expanding evidence for the potential utility of inhibiting FABP5,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo. “These important scientific advances show that lipid modulation is a promising therapeutic strategy across multiple diseases where overactivity of the lipidome contributes to the pathology of the disease or where modulation of the lipidome leads to increased levels of analgesic and anxiolytic lipids.

Artelo总裁兼首席执行官格雷戈里·戈尔加斯（GregoryD.Gorgas）表示：“我们很高兴与大家分享抑制FABP5潜在效用的不断扩大的证据。”。“这些重要的科学进展表明，脂质调节是多种疾病的一种有前途的治疗策略，其中脂质组的过度活跃会导致疾病的病理，或者脂质组的调节会导致镇痛和抗焦虑脂质水平的升高。

We are grateful for the opportunity to share our data and why we believe development of FABP5 inhibitors from our extensive library could have significant impact for a wide range of diseases. We expect to report on first-in-human trials with ART26.12 next year.”.

我们非常感谢有机会分享我们的数据，以及为什么我们认为从我们广泛的文库中开发FABP5抑制剂可能对多种疾病产生重大影响。我们预计明年将用ART26.12报告首次人体试验。”。

About ART26.12

关于ART26.12

Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN).

脂肪酸结合蛋白（FABPs）是一类细胞内蛋白，可伴侣脂质，包括内源性大麻素和脂肪酸。FABP在许多病理学中过度表达并与异常脂质信号传导相关。Artelo的主要FABP抑制剂ART26.12是一种有效且选择性的FABP5抑制剂，被开发为一种新型的外周作用非阿片类非甾体镇痛药，初步临床研究计划用于化疗引起的周围神经病变（CIPN）。

Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, and anxiety disorders..

除了ART26.12之外，Artelo广泛的FABPs小分子抑制剂库已显示出治疗某些癌症，神经性和伤害性疼痛以及焦虑症的治疗前景。。

About the International Cannabinoid Research Society

关于国际大麻素研究学会

The International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.

国际大麻素研究学会（ICRS）是全球首屈一指的科学协会，拥有来自40个国家的650多名国际成员，他们都是内源性、植物源性和合成大麻素及相关生物活性脂质领域的活跃研究人员。。

The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain..

ICRS研讨会将于2024年6月30日至7月5日在西班牙萨拉曼卡举行。。

About Artelo Biosciences

关于Artelo生物科学

Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation.

Artelo Biosciences，Inc.是一家临床阶段制药公司，致力于开发和商业化专有疗法，该疗法可调节脂质信号传导途径，包括内源性大麻素系统。Artelo正在推出一系列广泛适用的候选产品，旨在解决多种疾病和病症（包括厌食症、癌症、焦虑症、疼痛和炎症）中未满足的重大需求。

Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information and to view available publications, please visit https://artelobio.com/science/..

在久经考验的生物制药高管与备受尊敬的研究人员和技术专家的合作下，该公司应用领先的科学，监管和商业学科来开发高冲击疗法。有关更多信息和查看可用出版物，请访问https://artelobio.com/science/..

Forward Looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature.

本新闻稿包含《1933年证券法》第27A节、《1934年证券交易法》第21E节和《私人证券诉讼改革法》修订版所指的某些前瞻性声明，包括与公司产品开发、临床和监管时间表、市场机会、竞争地位、可能或假定的未来经营成果、业务战略、潜在增长机会和其他具有预测性质的声明有关的前瞻性声明。

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms.

这些前瞻性陈述基于当前对我们经营的行业和市场的期望、估计、预测和预测以及管理层当前的信念和假设。这些陈述可以通过使用前瞻性表达来识别，包括但不限于“期望”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜力”、“预测”、“项目”、“应该”、“将会”以及类似的表达和这些术语的否定之处。

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

这些报表与未来事件或我们的财务业绩有关，涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、业绩或成就与前瞻性报表明示或暗示的任何未来结果、业绩或成绩存在重大差异。

Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.

这些因素包括公司向证券交易委员会提交的文件中规定的因素，包括我们未来筹集额外资本的能力。警告潜在投资者不要过度依赖此类前瞻性声明，这些声明仅在本新闻稿发布之日起生效。

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new.

公司没有义务公开更新任何前瞻性声明，无论是由于新的。

Investor Relations Contact:

投资者关系联系人：

Crescendo Communications, LLC

Crescendo通信有限责任公司

Tel: 212-671-1020

电话：212-671-1020

Email: ARTL@crescendo-ir.com

电子邮件ARTL@crescendo-ir.com